CGRP monoclonal antibodies: erenumab

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

CGRP monoclonal antibodies: erenumab. It is indicated if migraine frequency is at least four days a month. Fully referenced neurology checklist.

Dose and administration

  • It is indicated if migraine frequency is at least four days a month
  • The initial dose is 70mg SC monthly
  • The dose may be increased 140mg monthly
  • It should be allowed to warm up to temperature before administration

General complications

Locked: subscribe to see this section.

Systemic complications

Locked: subscribe to see this section.

Acronym

Locked: subscribe to see this section.

References

  1. Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15:382-390. 
  2. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16:425-434.
  3. Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology 2017; 89:1237-1243. 
  4. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. NEJM 2017; 377:2123-2132. 
  5. Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38:1026-1037.
  6. And 9 more. Subscribe to see the full list

Related checklists

Loading...